1. In Vivo
  2. >>Outlook

Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

Sandoz, Viatris Look To Be In Commercial Vanguard; Supply Core, CDMOs Vital

 
• By Dean Rudge

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Generics producers are keen for a piece of the GLP-1 pie

With the addition of weight loss and obesity indications and more patient-friendly dosing regimens beginning at the start of the current decade, glucagon-like-peptide-1 (GLP-1) receptor agonists have exploded into a multi-billion-dollar, cultural phenomenon, comparable in the prescription pharma space to the arrival of Viagra (sildenafil) in the late 1990s or Botox before it.

The global market for such products has been tipped to reach $71bn by 2032, or even as high as $100bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

 
• By Jo Shorthouse

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

Biopharma Plumps Pipeline With Healthy Weight Loss Candidates

 
• By Melanie Senior

Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.

Benzos to Breakthroughs: Bill Burns on Roche's Transformation

 
• By Jo Shorthouse

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.

Medtech Industry Reaches New Chapter In Its Structural Evolution

 
• By Ashley Yeo

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

More from Growth

Deals In Depth: May 2025

 
• By Maureen Riordan and Deanna Kamienski

Seven $1bn+ alliances were penned in May, and four exceeded $2bn.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.